Aim: 11C-and 18F-choline PET/CT have been established as a promising modality in the assessment of prostate cancer patients1. However, it suffers to detect small malignant lesions. 68Ga-PSMA (PSMA) PET/CT showed promising in the detection of small lesions with a high tumor to background contrast2. This study was designed for comparison of detection rate between PSMA and 18F-fluoromethylcholine (FCH) PET/CT scan in pre or postop prostate cancer patients. Methods: In this prospective study 15 consecutive prostate cancer patients (mean age 67.9, range 57-83) underwent both PSMA and FCH PET/CT with a maximum interval of 4 weeks without any treatment in between. The imaging modalities were performed in 9 patients (mean age: 70.3; range: 63-83) in pre-and 6 Patients (mean age: 64.2; range: 57-71) in post-operative setting. Prostate cancer patients with histopathologic verification or biochemical recurrence were included in this study. Patients with systemic therapy and known second cancer were excluded. Pathologic findings in each imaging modalities have to be clarified histopathologically or by conventional imaging modalities and/or clinical follow-up. Results: Staging: The mean of PSA was 35.1 ng/ml (range: 3.44 -81.17 ng/ml). Pathologically increased tracer uptake was detected on both imaging modalities in the prostate gland in all patients [mean size on PSMA PET/CT: 20 mm (range: 12-43); FCH PET/CT: 23.6 mm (range: 12-34) & mean SUVmax on PSMA PET/CT: 16.2 (range: 6.1-28.1); FCH PET/CT: 7.4 (range: 3.6-15.9)]. Overall, a total number of 15 and 14 positive lymph nodes were detected on PSMA PET/CT and FCH PET/CT images, respectively. Malignant lymph nodes showed significantly higher uptake on PSMA-comparing FCH PET/CT [mean SUVmax on PSMA PET/CT: 12.8 (range: 2.8-34); FCH PET/CT: 6.6 (range: 2.3-11.9)]. However, there was no appreciable difference in the tracer intensity of the detected bony lesions in each modality. Restaging: The mean of PSA was 2.3 ng/ml (range: 0.48 -5.35). Local recurrence with pathologically increased tracer uptake was detected in one patient on both imaging modalities, However, it shows markedly higher uptake on PSMA PET/CT (SUVmax: PSMA: 12.4; FCH: 4.9). In addition, PSMA PET/CT was able to detect higher number of metastatic lymph nodes compared with FCH PET/CT (14 vs. 10) with significantly better tumor to background ratio (SUVmax 8.7 on PSMA vs 4.45 on FCH).
Aim: This survey aims at gathering information about PET/MR operations worldwide to determine the current clinical applications of PET/ MR imaging. Methods: An internet-based survey of active PET/MR users was ran between 05/2015 and 08/2015 using surveymonkey. All 69 active PET/MR sites were invited to partake in this survey. The survey was composed of 37 questions related to (A) PET/MR center and installation, (B) variations in imaging protocols and (C) potential future applications. Aim: Injury to the anterior cruciate ligament (ACL) is common, particularly among young athletes. Reconstruction with a graft helps restore stability and function to the knee, as the graft heals through the process of ligamentization1. Anatomic imaging alone cannot provide insight as to the progress of graft ligamentization, however. Combined 18F-FDG PET/MR imaging on current systems has been shown to be feasible for the evaluation of ACL graft viability following reconstructive surgery. We evaluated the capabilities of high resolution PET/MRI through combined use of a next generation digital photon counting PET/CT and 3 T MRI in an on-going multi-modality imaging study for the assessment of graft viability. Methods: 10 patients had a standard of care MRI on a 3 T Ingenia CX. Proton density and T1 weighted sequences were acquired on all three planes, with a 3D high resolution image acquired on the sagittal plane. Low-dose PET/CT acquisitions were performed on the Vereos digital PET/CT (all Philips Healthcare). A foam mold of the MR knee coil was used to match knee positioning between PET and MR acquisitions. A single bed position centered on the knees was acquired following a 111 MBq 18F-FDG injection. Listmode data were reconstructed using a 144x144 matrix with 4 mm3 voxel volumes, a 288x288 matrix with 2 mm3 volumes, and a 576x576 matrix with 1 mm3 voxel volumes. Each reconstruction matrix size also used the option of a Gaussian filter and point spread function correction. Patients were grouped according to time since surgery and SUVmax was measured in the proximal, middle, and distal portions of the graft, femoral and tibial tunnels, and the posterior cruciate ligament (PCL), and quadriceps muscle for reference. Matched ROIs were drawn in the contralateral healthy knee. Results: In all cases, PET and MR images were readily co-registered for quantitative evaluation. Excellent image quality was seen at all reconstruction matrix sizes, with the smaller voxel volumes improving visual evaluation of the heterogeneity of uptake throughout the evaluated ACL grafts. As previously validated in phantom tests, the use of smaller voxel volumes also improved quantification of graft metabolic uptake. SUVs measured on 2 and 1 mm3 images were found to be greater than those of default 4 mm3 images for regions of interest in the graft and bone tunnels. SUVs in background regions were less affected by the change in reconstruction matrix size. Addition of the Gaussian filter and point spread function correction during reconstruction further improved visual and quantitative precision. As in previous evaluation of ACL grafts by conventional PET, the trend was seen whereby the metabolic activity in the graft and bone tunnels decreased with longer recovery times since surgery. Conclusion: PET/MRI imaging of the knee, particularly ACL grafts, benefits from the improved signal to noise and capacity for higher resolution reconstruction facilitated by use of PET digital photon counting and digital MR coil systems. The primary advantage in digital PET imaging of small structures is due to the improved quantitative precision enabled by a reduction of partial volume effects. Higher matrix PET reconstruction also enables better voxel-wise registration to MRI. The improved accuracy of quantification with digital PET will allow for more detailed analysis and correlation with clinical evaluations of graft healing and rehabilitation planning following reconstructive surgery. Aim: The selection and utilization of Yttrium-90 (90Y) microspheres as a targeted radiotherapeutic is driven by the existing clinical need to selectively embolize tumor-induced vasculature and deliver high doses of therapeutic radioactivity to unresectable liver lesions. This is particularly important when external beam radiation therapy is deemed impractical. Bremsstrahlung imaging currently serves as the standard for post-90Y radioembolization assessment but this approach is limited with poor image quality, poor 90Y-to-background contrast, and limited capability for post-therapy quantitative dosimetry. Although it emits high-energy electrons for therapeutic purposes, 90Y is a theranostic agent given that it also produces a small fraction of discrete annihilation photons which are imagable with conventional photomultiplier tube-based PET technology (cPET/CT, [1] ). A recent technological innovation has replaced these conventional photomultiplier tubes in the PET gantry with next-generation, solid-state, digital photon counting PET detectors (digital PET or dPET) which have Time-of-Flight capability as well as markedly improved timing resolution. Our aim is to assess the clinical impact of Time-of-Flight on 90Y dPET/CT image quality and post-therapy assessment in patients following liver radioembolization. Methods: In an ongoing trial, we are using a pre-commercial release digital PET/CT system (Vereos, Philips Healthcare) to image and assess 90Y microsphere biodistribution in patients with malignant/metastatic liver lesions after radioembolization therapy. Bremsstrahlung SPECT/CT imaging was performed within a few hours immediately following radioembolization with a total image acquisition time of 22 m. Digital PET imaging was performed in 10 patients at 4 -50 h following liver radioembolization with a total image acquisition time of 21 m. PET data were reconstructed using a 3D OSEM algorithm with and without Time-of-Flight using a voxel size of 4x4x4 mm3. Image characteristics and isocontour volumes of 90Y activity were then assessed by matched comparison using the Intellispace Portal workstation (Philips). In addition, matched comparison with standard bremsstrahlung SPECT/CT imaging (Symbia T16, Siemens Healthcare) was performed to further assess the practicality and clinical utility of this dPET/CT imaging approach. Results: For all patients, dPET images were rated as evaluable and, when compared with bremsstrahlung SPECT/CT, dPET detection of 90Y radioactivity enabled markedly improved qualitative and volumetric assessment of 90Y microsphere biodistribution. In particular, dPET/CT technology enables post-therapy 90Y imaging with shorter image acquisition times, improved image quality, contrast, and volumetric assessment when compared with standard bSPECT/CT approaches. Furthermore, Time-of-Flight improved overall image quality and 90Y-to-background contrast for dPET/CT images when compared with non-Time-of-Flight dPET but there were no significant differences in the measured intrahepatic volumes of 90Y activity using 1 % isocontours. Conclusion: There remains an unmet clinical need to improve qualitative and quantitative imaging assessment of 90Y-based radiotherapies. Current imaging approaches for assessing 90Y in vivo are (1) challenging in terms of low quality / poorly quantitative bremsstrahlung techniques and (2) potentially disruptive to clinical workflows given the long image acquisition times needed for current cPET techniques. We demonstrate that Time-of-Flight dPET image quality is superior to the non-Time-of-Flight dPET and standard bremsstrahlung approaches. Using dPET technology in the future, we expect that new strategies for 90Y image acquisition as well as new reconstruction methodologies will facilitate even shorter image acquisition times with better image quality and more accurate dose quantification in patients treated with existing and new 90Y-based theranostics. [3] extended). PET data were acquired on the Siemens High Resolution Research Tomograph in Manchester and on the GE Advance PET scanner in Vienna. Atlas based regions of interest were defined in the ipsilateral TL on individual magnetic resonance images and time-activity curves extracted from the co-registered dynamic PET images [1, 3] . Metabolite corrected arterial input functions were used to estimate the net influx of VPM from plasma into brain (K1) from the first 10 min of PET data [1, 3] . Clinical follow-up data on seizure activity and anti-epileptic medication were available for 4 ± 1 years for Manchester and 6 ± 1 years for Vienna patients. Ranking of surgery outcome was done according to the modified Wieser's classification (best outcome assigned rank 1) [3] .
A10
Results: Correlation of VPM K1 values in ipsilateral TL with surgery outcome rank in individual patients was highly positive (Pearson r = 0.7573, p = 0.0017, n = 14). Patients with the highest Pgp activity (lowest K1 values) before surgery showed optimal surgery outcome (seizure and medication free) whereas those with the lowest Pgp activity continued to have seizures and to take medication even after surgery. Findings were consistent for both centres.
Conclusion: Pooled analysis of pre-operative VPM PET data consistently predicted outcome after TL epilepsy surgery in two centres, confirming findings from a previous pilot study. PET measurement of Pgp function should be further evaluated as an imaging biomarker for the prediction of TL epilepsy surgery outcome. Aim: The melanin concentrating hormone (MCH) is a cyclic neuropeptide which is predominantly expressed in the lateral hypothalamus and zona incerta [1, 2] . The biological effect is mediated by two G-protein coupled receptors (GPCR), the MCH receptor 1 and 2 (MCHR1 and MCHR2) [3] . Changes in the expression of the MCHR1 have been shown to be involved in a variety of pathologies, such as depression and anxiety disorders and are related to the central mechanisms of obesity [4, 5] . In this regard, the preparation and first in-vitro studies of [18F]FE@SNAP and [11C]SNAP-7941, as potential positron emission tomography (PET) radiotracers for the visualization of the MCHR1, were performed successfully [6, 7, 8, 9] . Based on the preceding results the present present study aimed at a fur- Experiments on blank CHO-K1 cells were performed to determine unspecific binding. In-vivo: Small-animal μPET/CT and μMRI imaging was performed in naïve male Sprague Dawley rats (HIM:OFA; 438 ± 42 g). The rats were anesthetized with isoflurane/oxygen (1.5 % / 0.8 mL) and [18F]FE@ SNAP was administered through the lateral tail vein (47.8 ± 1 MBq; SA: 19.7 ± 6GBq/μmol). Radiotracer uptake in the brain (SUV; g/mL) was determined under i) baseline conditions, ii) blocking with 15 mg/kg SNAP-7941 and iii) blocking with 15 mg/kg tariquidar. After the imaging the rats were sacrificed, the organs were harvested and subjected to radioactivity measurements. The resulting values were expressed as percent injected dose per gram tissue (%ID/g). Further in-vivo investigations with respect to peripheral MCHR1 expression of healthy, obese and diabetic rats need to be performed to further proof the applicability of the MCHR1 concept.
A14
Reducing time in quality control leads to higher specific radioactivity of short-lived radiotracers L Nics Aim: Time plays a pivotal role in the preparation of radiopharmaceuticals (RP) labeled with short-lived radionuclides (e.g. carbon-11, nitrogen-13, gallium-68). In particular, it has to be taken into account that radioactive decay starts to reduce available activity as soon as the produced radionuclide is delivered to the synthesis unit. This is also true for the specific radioactivity (SA; activity per mass unit) which is of significant importance for radiotracers targeting saturable targets such as transporters or receptors. This process lasts until application of the RP after passing the quality control (QC) and final release of the product. So far, time reduction was mostly implemented during the chemical synthesis process or subsequent purification. In contrast, QC procedures were not considered to a full extent in that perspective. Determination of radiochemical purity and SA normally requires the use of high performance liquid chromatography (HPLC) which is also the most time-consuming step in the QC procedure. Recently, Nakao et al. [1] suggested a method involving hybrid (ultra-)HPLC ((U)HPLC) to shorten run times. Hence, aim of this work was to implement fast HPLC for [11C]DASB and (+)-[11C]PHNO to enhance specific radioactivity. Methods: [11C]DASB and (+)-[11C]PHNO were prepared according to methods described in detail elsewhere. [2, 3] All analytical HPLC analyses were performed on an Agilent 1260 system equipped with a quaternary pump, a multi wavelength UV-detector, a manual injector and a radiodetector and controlling software. HPLC column was a Waters X-bridge BEH Shield RP-18 (4.6 x 50 mm, 2.5 μm, 130 Å). Injection volume was 5 μL. Aim: Erlotinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) used to treat patients with non-small cell lung cancer (NSCLC). NSCLC patients with activating mutations (e.g. exon 19 deletion) in the EGFR gene have increased response rates to erlotinib treatment compared to patients with wild-type EGFR. However, patients with activating EGFR mutations eventually develop resistance to erlotinib caused by secondary mutations (e.g. T790M). 11C-erlotinib PET signal was found to be higher in NSCLC tumors with an activating EGFR mutation than in tumors with wild-type EGFR [1] . It is however, not known if 11C-erlotinib PET will be able to distinguish tumors with secondary resistance causing mutations from erlotinibsensitive tumors. Aim of this study was to measure in vitro 11C-erlotinib binding in erlotinib-sensitive and erlotinib-resistance cancer cell lines. Methods: One glioblastoma (U-87 MG) and four NSCLC (erlotinib-sensitive HCC827, erlotinib-resistant HCC827, gefitinib-resistant HCC827, and erlotinib-resistant HCC827 with a secondary EGFR mutation) cell lines were incubated with 11C-erlotinib up to 60 min. In a second set of experiments cell lines were pretreated with unlabeled erlotinib or different P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitors (elacridar, Ko143, tariquidar) and then incubated with 11C-erlotinib for 30 min. Retained radioactivity in the cells was measured in a gamma counter and normalized to cell count. Results: Uptake of 11C-erlotinib was significantly lower in U-87 MG cells compared to all NSCLC cell lines. No significant differences were observed in the uptake of 11C-erlotinib between the four NSCLC cell lines. In all NSCLC cell lines 11C-erlotinib uptake was significantly reduced following pretreatment with unlabeled erlotinib, which was not the case for U-87 MG cells. Pretreatment with elacridar, Ko143 or tariquidar had no effect on 11C-erlotinib uptake in all tested cell lines. Conclusion: We found significantly lower uptake of 11C-erlotinib in U-87 MG cells with wild-type EGFR compared to all NSCLC cell lines, which had activating EGFR mutations. No significant differences in 11C-erlotinib uptake were observed between erlotinib-sensitive, erlotinib-resistant, and gefitinib-resistant NSCLC cell lines. In all NSCLC cell lines a significant reduction of 11C-erlotinib uptake after pretreatment with unlabeled erlotinib was found, suggesting specific binding to EGFR. Efflux of 11C-erlotinib by P-gp and BCRP was not evident in any of the studied cell lines. Taken together, our findings suggest that 11C-erlotinib PET may be suitable to distinguish wild-type EGFR from EGFR with activating mutations, but unsuitable to identify secondary resistance causing mutations. To further extend our in vitro findings, PET studies will be carried out in tumor-xenografted nude mice using erlotinib-resistant and erlotinib-sensitive NSCLC cell lines. (1) Pretargeting means splitting of the tracing compound into a marker, which is enriched in target tissue and a radiolabeled pull down reagent (PDR). By using such an approach, longer periods of time for enrichment of the marker compound can be provided, which is crucial for PET measurements with high contrast of target to normal tissue. After this labeling step the PDR is injected, which should react with the trapped marker in a bioorthogonal way. This would allow the use of short living radioisotopes in PET imaging of slow accumulating markers and leads to enhanced signal-to-noise ratios and lower radioactivity doses. The most prominent bioorthogonal reaction, the strain-promoted azide alkyne cycloaddition (SPAAC), has been used in a wide variety of applications in chemical biology and biomedicine. (2) This reaction features the Huisgen-Cycloaddition between an azide and a strained cycloalkyne to form triazoles. SPAAC has already been used in pretargeted PET imaging featuring short lived 18F as radionuclide by Lee et al. (3) although they do not report about biodistribution and stability of the azide-labeled pull-down-reagent. Aim of this work was the synthesis and in vivo evaluation of 18F labeled azidoglucoses as pull-down reagent for pretargeted PET imaging using SPAAC as bioorthogonal ligation. Using glucose derivatives as PDRs has several advantages, such as good and fast biodistribution and possible active uptake into cells by glucose transporters. Blocking of the 6 position with 18F will prevent phosphorylation and therefore trapping in cells can only occur after bioorthogonal reaction. Two different isomers were evaluated, both containing 18F at position 6 while either 1-OH (18F-AzFDG16) or 2-OH (18F-AzFDG26) was displaced against an azide group. Methods: Precursors for radiosynthesis were prepared in 4 and 3 steps respectively starting from commercially available material. Radiosynthesis were carried out by nucleophilic displacement of a nosylate by 18F-Fluorine followed by alkaline hydrolysis on a tC18 SepPak cartridgeand formulation in saline solution. In vivo studies were performed by administration of 18F labeled azidoglucoses to female BALB/c mice followed by dynamic PET imaging (n = 6 for 18F-AzFDG16, n = 4 for 18F-AzFDG26) for 120 min. At the end of the imaging experiment the mice were sacrificed and harvested urine and plasma samples were screened for radiometabolites using radiothin-layer-chromatography (TLC). Selected organs were withdrawn and gamma counted to validate data from the last PET time frame. Results: 18F-AzFDG16 and 18F-AzFDG26 were obtained in good yields and high radiochemical purity. PET Imaging revealed a very homogenous and fast biodistribution of both substances in all regions in the body excluding the brain, as well as rapid renal excretion. Furthermore, PET imaging revealed no significant extent of in vivo defluorination of both PDRs, since no enhanced radioactivity uptake in bone was observed. High Stability of these reagents was also confirmed by metabolite analysis (radio- Aim: Slow tracer accumulation of imaging probes can be circumvented by pretargeting using bioorthogonal ligations. These fast and biocompatible "click" reactions are capable of forming a covalent linkage between a pre-administered marker and a labeled pull down reagent (PDR) in vivo. Due to particular high ligation rates the inverse electron demand Diels-Alder reaction (IEDDA) of strained dienophiles with 1,2,4,5-tetrazines (Tz) has gained interest in nuclear medicine. Until recently, only few radiolabeled tetrazines mainly based on radiometals and bulky chelating agents have been reported. However, the use of short-lived PET isotopes (18F, 11C) with favorable decay characteristics and high specific activity was limited due to chemical stability and reactivity restrictions. Within this contribution an overview will be given describing the concept of bioorthogonal PET imaging. Furthermore the development of various low molecular weight radiotetrazine probes labeled with fluorine-18 and carbon-11 will be presented. Methods: In silico methods were used to investigate IEDDA ligation reactivity prior to synthesis. Tetrazines were synthesized using metal catalysis, and precursor substances (tosylates for 18F-radiochemistry, primary amines for 11C-radiochemistry) were labeled in good radiochemical yields avoiding the use of prosthetic groups. Radiochemical purity was assessed by radio-HPLC and TLC, and the identity of labeled PDRs was verified by co-injecton with non-radioactive reference materials. Biodistribution and excretion kinetics were investigated by administration into female BALB/c mice and whole body dynamic PET/MR scanning for 120 min (18F) or 60 min (11C). Furthermore blood and urine samples were analyzed for radiometabolites and gamma counting of selected organs was conducted to confirm PET results.
Results: A set of several tetrazine probes labeled with fluorine-18 and carbon-11 was developed. The compounds 3-(3-[18F]-Fluoropropyl)-6-methyl-1,2,4,5-tetrazine and N-[11C]-methyl-1-(6-methyl-1,2,4,5-tetrazin-3-yl)methanamine exhibit high metabolic stability, homogenous biodistribution (including the brain) and fast excretion making them valuable candidates to be used as PDR in pretargeted PET applications. Other 18F-tetrazines were found to be metabolically unstable but still proved highly valuable to be used for rapid radiolabeling of dienophile-tagged biomolecules.
Conclusion:
To this end a selection of promising bioorthogonal tools is available that should allow for pretargeted PET imaging of slow accumulating probes as well as rapid radiolabeling in highly complex (biological) matrices.
Aim:
The human adenosine-3-receptor (hA3R) is highly expressed in various tumor cell lines. (1) Aim: In recent years the concept of pretargeted PET imaging using bioorthogonal chemistry has drawn a lot of attention as it allows imaging of slow accumulating probes with short-lived radionuclides leading to enhanced signal-to-noise ratios and lower patient radiation doses. The underlying idea is based on a two-step approach that includes administration of a target tissue (e.g. tumor) sensitive probe followed by a radiolabeled pull down reagent (PDR). The probe and PDR will ligate in vivo via a bioorthogonal reaction, which does not interfere with native biochemical processes and exhibits high reaction rates. Aim: In radiochemistry, main focus is set on time efficiency, automated syntheses as well as high chemical conversion. To meet these requirements, microfluidic devices have been tested for downsizing the precursor amount of already established radiosyntheses during the last years [1] . This approach usually enables an enhanced conversion due to a high surface-to-volume ratio [2] . Microfluidic devices have scarcely been tested for Ga-68-radiolabeling so far [3] . The aim of this study was to test the feasibility of using a fully automated microfluidic system containing a flow-through reactor for the radiosynthesis of Ga-68-PSMA-HBED-CC.
Methods: Ga-68-radiolabeling of PSMA-HBED-CC (ABX, GMP grade) was performed using an Advion NanoTek LF system containing a flow-through microreactor that consists of a silica capillary (l = 2 m, Ø100 μm, V = 15.6 μL). 68Ga3+ was obtained from a Ge-68/Ga-68 generator (3.7 GBq; Obninsk) and the eluate was collected according to a fractionized protocol. Roughly 400 μL of the peak activity were loaded into the storage loop within the NanoTek system and aliquots of different volumes were used for subsequent reactions. For optimization of PSMA-HBED-CC radiolabeling different flowrates (i.e. 30, 50, 80 μL/min), reaction volumes (40-740 μL), temperatures (25-150°C) and precursor concentrations (0.2-3 nmol) were evaluated. NaOAc-and HEPES-solutions (1.5 M) were used for pH adjustment. Results: Ga-68-radiolabeling of PSMA-HBED-CC (ABX, GMP grade) was performed using an Advion NanoTek LF system containing a flow-through microreactor that consists of a silica capillary (l = 2 m, Ø100 μm, V = 15.6 μL). 68Ga3+ was obtained from a Ge-68/Ga-68 generator (3.7 GBq; Obninsk) and the eluate was collected according to a fractionized protocol. Roughly 400 μL of the peak activity were loaded into the storage loop within the NanoTek system and aliquots of different volumes were used for subsequent reactions. For optimization of PSMA-HBED-CC radiolabeling different flowrates (i.e. 30, 50, 80 μL/min), reaction volumes (40-740 μL), temperatures (25-150°C) and precursor concentrations (0.2-3 nmol) were evaluated. NaOAc-and HEPES-solutions (1.5 M) were used for pH adjustment. Conclusion: To the best of our knowledge, we were able to demonstrate for the first time the successful microfluidic Ga-68-radiolabeling of PSMA-HBED-CC. Moreover, we observed that radiochemical conversion can be further enhanced, when purging the system with all reagents prior to syntheses. This proof-of-principle might lead to increased availability of Ga-68-tracers following the dose-on-demand principle. Aim: 24-nor-ursodeoxycholic acid (norUDCA) is a novel therapeutic approach to cholestatic liver diseases. In mouse models of cholestasis norUDCA induces basolateral multidrug resistance-associated proteins 4 and 3 (Mrp4, Mrp3) in hepatocytes, which provide alternative escape routes for bile acids accumulating during cholestasis but could also result in altered hepatic disposition of concomitantly administered substrate drugs. Aim: Production of 18F-flumazenil from 2-nitroflumazenil under GMP conditions is primarily performed with manipulators or custom built radiosynthesis modules with fixed components, as the use of N,Ndimethylformamide (DMF) at 160°C prohibits the use of commonly available disposable cassettes. Cassettes for the GE TRACERlab MXFDG synthesis modules are commercially available in different materials. ROTEM Industries and GE Healthcare use polysulfone as the main component, and it is known that this polymer is not compatible with DMF. Cassettes from ABX are reportedly more chemical resistant, with polypropylene as its main constituent. The aim of this work was to establish a robust automated radiosynthesis procedure for 18F-flumazenil on the GE TRACERlab MXFDG, where staff previously trained on the same equipment can easily perform the radiosynthesis. Methods: Fragments of the ABX FDG cassette was exposed for 1 or 24 h to various solvents including acetonitrile and DMF at room temperature (RT) or 60°C to assess its chemical resistance. A new synthesis sequence was written for the GE TRACERlab MXFDG. A non-radioactive test run was performed with the ABX FDG cassette, and radiosynthesis was carried out with the cassette components replaced by chemically resistance manifolds (ABX). Results: Incubation of the PP ABX FDG cassette fragments in acetonitrile at RT showed no macroscopic influence on the polymer while the fragment became soft and mouldable at 60°C. Visible changes occurred after 1 h incubation with DMF, with the polymer having completely dissolved after 24 h, regardless of temperature. To verify the implication of these results on a 1 h radiosynthesis, a test run was performed using the same cassette material and synthesis conditions without radioactivity. Parts of the manifold was found to have cracked, and a valve blockade was observed due to polymer melting. Radiosynthesis was carried out with the manifolds replaced by chemically resistant ones, and 18F-flumazenil was successfully obtained in 4 % decay corrected yield. Conclusion: Disposable cassettes assembled with chemically resistant manifolds is a requirement for the automated synthesis of 18F-flumazenil from 2-nitroflumazenil using the GE TRACERlab MXFDG synthesis module. Neither reagent kits nor program sequences are hitherto commercially available, but GMP grade production can nonetheless be successfully carried out with modifications on existing equipment. Aim: Over the last years, peptide receptor radiotherapy (PRRT) using 177Lu in the treatment of neuroendocrine tumours (NET) and prostate cancer (PCa) has become a major issue in nuclear medicine. Consequently, the safe and reliable production and quality control of therapeutic amounts of suitable radiopharmaceuticals, i.e. 177Lu-DOTA-TATE and 177Lu-HA-DOTA-TATE ("high affinity DOTA-TATE") for NET-treatment as well as 177Lu-DOTA-PSMA (PSMA-617) against PCa, had to be established and optimized. Similarities and differences in the set-up are reported in this work. Methods: 177Lu-radiolabelling was performed using the cassettebased ModularLab PharmTracer® synthesizer (EZAG, Berlin, Germany) and starting activities of 9.0-19.0GBq 177LuCl3 (no-carrier-added; itg, Munich, Germany) in 0. . All precursors were of GMP quality. Crude 177Lu-DOTA-TATE/-HA-DOTA-TATE was purified on a C18 SPE cartridge without any further dilution, whereas 177Lu-DOTA-PSMA was first prediluted with 2 ml saline (0.9 %), before purification on a C18-SepPak by washing with 2 ml saline (0.9 %). Elution was done with 2 ml ethanol (48 %) and the product was transferred and 0.22 μm-filtrated to the product vial together with 16 ml saline (0.9 %). To all 177Lu-DOTA-peptide-formulations 0.5-1.2 ml DTPA (3 mg/ml) was added. Full radiopharmaceutical quality control was performed for all 177Lu-peptide formulations (e.g. radio-TLC-, HPLC-, pH-, sterility-and apyrogenicity testing).
Results: 177Lu-labelling of DOTA-coupled somatostatin analogues was introduced at the Medical University / General Hospital of Vienna in 2010 and 177Lu-DOTA-TATE-syntheses were performed until 2015 (n = 109). Due to legal restrictions in the availability of DOTA-TATE precursor we recently switched to the use of 177Lu-HA-DOTA-TATE (n = 13, so far). Also this year, the production of 177Lu-DOTA-PSMA was implemented (n = 14, so far). All 177Lu-productions took about 45 min (synthesis, including conditioning, purification and sterile filtration) plus 120 min for preparation of the devices plus 60 min for QC. The synthesis failure rate was 99 %. All 177Lu-lots were sterile and endotoxins were <1EU/ml. The HA-DOTA-TATE-precursor was somewhat less soluble than DOTA-TATE. 177Lu-DOTA-PSMA showed a slightly different chromatographic behaviour in TLC and HPLC compared to 177Lu-DOTA-TATE and 177Lu-HA-DOTA-TATE. Conclusion: Both the somatostatin analogues 177Lu-DOTA-TATE and 177Lu-HA-DOTA-TATE for NET-treatment but also 177Lu-DOTA-PSMA for treatment of PCa could be safely produced in activities up to <16GBq (2 therapeutic doses) and excellent quality under observation of proper radioprotection and radioactive waste management. Differences in the preparations were of minor concern. Set-up for the 3 different radiotherapeutics could be easily adapted. Aim: PSMA is a most promising ligand for imaging and therapy of prostate cancer lesions. Ever since the DOTA conjugated ligand PSMA-617 is known, the DOTA ligand can be labelled with a broad range of radionuclides (1). Our aim was, on the one hand, to establish labelling of 68Ga-PSMA-617 for PET diagnosis, and on the contrary 177Lu-PSMA-617 for therapy. Both should be compliant to the GMP preparation methodology. Methods: The ligand PSMA-617 was purchased from ABX. 68Ga-PSMA-617 was prepared with a cationic purified (5 M NaCl, SCX PS-H+) 68GaCl3 (1.8 GBq Generator, IThemba). The labelling of 20 μg PSMA-617 was performed in HEPES solution at 125°C/6 min. The crude mixture was purified by C18 SPE. For 177Lu-PSMA-617, 200 μg PSMA-617 was labelled with 10 GBq 177LuCl3 (ITG) in sodium acetate/ascorbate buffer at 100°C/20 min. Then, the reaction mixture was diluted and sterile filtrated without further purification. Both kinds of synthesis was carried out with a Scintomics GRP synthesizer, sterile single use cassettes and the standard synthesis sequences for 68Ga-peptides respective therapeutic peptides. Results: 68Ga-PSMA-617 was obtained with a yield of 48 % at EOS (decay corr. 79 %). The labelling reaction was near quantitative, but 15 % (decay corr.) of 68Ga retained on the cationic exchange column during processing. The labelling to 177Lu-PSMA-617 was quantitative, there for the yield was >90 %. The radiochemical purity, determined to be HPLC was 96 % (68Ga-PSMA-617) and 92 % (177Lu-PSMA-617) due to detected impurities of labelled peptides. The detected amount of free radionuclides were always <1 %. 68Ga-PSMA-617 and 177Lu-PSMA-617 remained stable until the planned shelf live. Conclusion: The introduced preparation of 68Ga-PSMA-617 and 177Lu-PSMA-617 using Scintomics GRP synthesizer and standard synthesis sequences are robust and reliable processes, which meets the GMP rules. Aim: Liposomes (LPs) have been extensively investigated as nanocarriers for drug delivery. In this context, evaluation of their biodistribution pattern after administration into living organisms is of paramount importance. This can be achieved by incorporation of a γ-emitter radioisotope followed by in vivo imaging using single photon emission computed tomography (SPECT). Here, we present a method for radiolabelling LPs with the γ-emitter 67Ga. Regional distribution in the lungs after inhalation using a specially designed nebulisation chamber was determined using SPECT-CT. Methods: Gallium-67 (T1/2 = 3.26 days) was purchased from IBAMolypharma as 67Ga-citrate complex and converted into 67GaCl3 following a well established method.1 For the radiolabelling, 10 μL 8-hydroxyquinoline (10 mM in EtOH) in 100 μL sodium acetate buffer (100 mM pH 5.5, 150 mM NaCl) were added to 67GaCl3 (≈150 MBq in 0.1 M HCl). Immediately after, 100 μL of DTPA-containing LPs were added and the mixture was incubated at 37°C for 1 hour. 67Ga-liposomes were purified by size exclusion chromatography and radiochemical purity was assessed by radio-ITLC. Administration of the radiolabelled LPs was carried out under sedation using an only-nose exposition device coupled to a chamber equipped with a specially designed nebulizer. Biodistribution of 67Ga-liposomes was investigated by whole body SPECT-CT imaging. Dissection/gamma counting and ex vivo imaging experiments to assess the percentage of the nebulised dose deposited in the lungs and the accurate regional distribution, respectively, were also carried out. Results: Labelling efficiencies close to 45 % were achieved. After purification, radiochemical purity exceeded 95 % in all cases. Biodistribution data showed a uniform distribution of the labelled LPs in both lungs at short times after inhalation. The percentage of the nebulised LPs reaching the lungs was close to 0.5 %. Conclusion: Uniform distribution of the labelled LPs in the lungs is achieved with the new aerosol generator. The obtained data constitute a promising starting point for using liposomes as nanocarriers for antibiotics targeting the lungs of infected patients. Aim: SPECT imaging of dopamine transporters (DaT) with FP-CIT (DaTscan) is an established method for the diagnosis of neurodegenerative parkinsonism. Quantification of DaTscan (semi-automatic or full automatic) has been shown to reduce equivocal reporting of DaTscan and can be used as an adjunct to visual assessment. The recent published "European multicentre database of healthy controls" [1] showed significant age-related effects and gender differences in DaT levels in healthy controls. We developed a tool to integrate those normal physiological variances in the quantification of a single SPECT-examination. Furthermore the tool allows to build a large database for further statistical analysis. Methods: SPECT-acquisition was done on a GE Hawkeye dual head gamma-camera. Quality control showed longitudinal uniformity and centre of rotation within limits. SPECT acquisition and reconstruction were performed in concordance with the parameters described in the ENC-DAT study. Images were reconstructed without and with attenuation correction (using Chang's method). For further calculation only the results of the AC images were used. Quantification was done using BRASS fully automated functional brain analysis (Hermes, Sweden). Using standard Excel software (Microsoft Corporation, United States) a macro enabled worksheet was developped which 1) allows easy input of relevant parameters (including quantitative output of BRASS) for an individual patient, 2) create a result page with numerical and graphical results of the DaTscan-quantification and 3) builds a database from each input session. Results: In all patients (age ranging from 32 to 87 years; 31 male and 30 female patients) scheduled for DaTscan, quantification was performed with age and gender correction. The procedure is standardised and fully automatic and autonomously done by the medical imager. Physicians can report DaTscan with greater diagnostic confidence: all scans could be classified as normal or abnormal. A database of 61 patients is build since start of this tool: further statistical analysis will be performed in the future. Conclusion: Integreation of age and gender differences in quantification of DaTscan is feasible and applicable in clinical routine. The Philips software Intellispace Portal (ISP) was used to co-register 18F-FET PET data with most recent MRT images with a maximum interval of 42 days. A circular background area with 5 cm diameter drawn in the contra lateral hemisphere to glioma including white and grey matter was suitable to define a LBR of 1,6 as threshold between tumor and normal tissue. For calculating the lesion-tobackground ratio (LBR), the SUV max of the lesion was divided by the SUV mean of the background area. Clinical data on surgery, histology, chemotherapy, radiotherapy and WHO grade were obtained from all patients. Results: The mean LBR of low grade tumor was significantly lower compared with the LBR of high grade tumor (2,38 vs. 2,83 p = 0,006). The 95 % confidence interval ranged from 2,067 to 2,686 in low grade tumors, and from 2,695 to 2,967 in high grade tumors, respectively. The LBR cut-off value to differentiate between low grade and high grade tumors was 2,7. The mean LBR in patients without radiotherapy was not significantly different compared to patients undergoing the 18F-FET PET scan during or after radiotherapy (2,78 vs. 2,70 p = 0,560). The mean LBR in patients without chemotherapy was significantly higher than in patients undergoing the 18F-FET PET scan during or after chemotherapy (2,93 vs. 2,61 p = 0,023). Conclusion: This study confirms the validity of a cut-off LBR value of 2,7 for the differentiation of low grade and high grade glioma. (8 cm3). Following T/N ratios were evaluated: T/Nstandard (i.e. SUVmax/SUVmean), T/Npeak (i.e. SUVpeak/SUVmean), T/Nmax (i.e. SUVmax/ SUVmax) and T/Npp (i.e. SUVpeak/SUVpeak). Results: Our patient contingent was evenly distributed between low and high grade tumors (46 % low, 54 % high grade) according to the latest WHO definition (2007). Excluding oligodendrogliomas (ODG) 61 % of all gliomas without MRI contrast enhancement were low grade and 76 % of gliomas with MRI contrast enhancement were high grade gliomas. In ODGs only 58.5 % of non contrast agent avid gliomas were low grade and 54.5 % with verifiable uptake of contrast agent were high grade gliomas. Most frequently tumors were located in the frontal (44 %) followed by the temporal lobe (41 %). Visually improve image noise, local resolution and thus the demarcation of small lesions. Methods: TOF-18F-FDG PET/CT was prospectively performed in 20 patients with suspected pancreatic cancer. In all patients, a histopathologic confirmation was made. PET/CT images were performed 30 and 90 min. p.i. including a diagnostic CT of the upper abdomen with contrast medium and pancreas protocol. SUVmax of the lesions was measured and compared with and without TOF in the 30 and 90 min. p.i. images. Lesions with an increase of SUVmax on the delayed images were assessed as malignant, whereas lesions with a decrease of SUVmax were assessed as benign. The comparison of TOF-PET/CT with standard PET/CT images and the determination of cut-off values for malignant lesions were made using ROC-analysis. Results: Of 20 patients 11 patients had malignant and 9 patients a benign pancreatic lesion. In one patient IPMN could only be diagnosed correctly with TOF. Based on the histopathologic findings sensitivity, specificity and diagnostic accuracy for TOF were 100 %, 67 % und 85 % versus 90 %, 90 % and 90 % without TOF. ROC analysis of SUVmax with TOF 30 and 90 min p.i. yielded a cut-off value of 4.5 and 4.7, respectively with a sensitivity and specificity of 89 % and 100 % and 91 % and 100 %, respectively. The area under the curve (AUC)PET and AUCTOF-values showed no significant difference neither in the early nor the delayed images. Conclusion: Among patients with suspected pancreatic cancer, the use of TOF-PET/CT correlated due to a better anatomical localization and identification of pancreatic lesions with higher sensitivity. However, TOF-PET/CT is of no additional use in differentiating malignant and benign pancreatic lesions. To what extent patients can benefit from the higher statistical weighting of the sensitivity should be examined in a greater patient population. Aim: We propose a novel approach additional to inspection and parametric subtraction analysis aiming to avoid thyroid gland and thyroid nodule artifact in parathyroid lesions scintigraphy. Methods: 78 patients, median age of 58 (19-80) years, with clinical diagnosis hyperparathyroidism (PHPT) and ultrasound positive report of concomitant thyroid disease, underwent preoperative, dual-tracer: 99 m Tc-pertecnetat and 99mTc-MIBI, double-phase scintigraphy (EANM guidelines 2009). Specially designed software, we developed, examined ROI time/activity changes in matrix with different, optional sizes, up to maximal resolution (1,5 mm); with automatic imaging signal preprocessing (linear fitted TAC logarithm, ensamble coupling) and segmentation based on semi automatic TACs clustering of pixels as well as fractal analysis for noice/motion artifacts and time activity curves. We correlated our findings with PTH levels, histology results and conventional scintigraphic findings: subtraction and visual interpretation of planar images of neck and mediastinum in oblique sections, according to ultrasound PHPT localization and delayed scans in one hour interval Results: Following histopathology in A.: parathyroid autonomy 53/ 78pts: solitary-44pts, hyperplasia: 8pts-7/8patients with two lesion and 1/7 had all four lesions and one PT carcinoma; median lesion volume was 796 mm 3 . B: thyroid -benign nodule only: adenoma folliculare, colloides and cystica: 25/78(32 %)pts; malignancy: 15/ 78(19 %)pts-papillary 7pts and one for medullary; C.: concomitant PHPT and thyroid nodular disease occurred in 36/53pts, among them 8pts had thyroid malignancies. Parathormone (PTH) was median 125,2 pg/ml (range 70-658 pg/ml). Standard findings (subtraction, oblique planar scans and delayed phase) in total of 63 lesion (in 53 pts) had 10 FN (mostly in hypeplasia PTA), and PPV was 81 %; sensitivity 96 %, specificity 76 %. Using specially designed software, thyroid TACs represented exponentially declining curves but parathyroid lesions had typical uptake pattern in the form of late phase peak, independent to PTA volume and/or PTH levels. The ratio of PTA-to-normal thyroid uptake at peak maximum was 1.35(±0.21). Parameters of optimal PHPT curve enabled visual interpretation. Fractal theory was helpful in matrix 5x5 designing classifier dimension 1.1-1.3 for automatic procedure. A new processing method had PPV 97 %, sensitivity 98 %, and specificity 96 %. The thyroid gland washout was up to 28 % in normal, adenoma or thyroid carcinoma tissue and their slope analysis of TACs had equivocal negative slope: −0.04. Conclusion: New quantification method and dedicated software as well as high computational power facilitate the recognition of small parathyroid lesions in the presence of concomitant thyroid nodular disease, overcoming diagnostic problem present in conventional as well as SPECT/CT and PET/CT imaging.
A33
PET-CT scan the oncologist decided to perform an adjuvant chemotherapy. PET-CT will be performed during and at the end of the treatment for the evaluation of the response. Conclusion: This case confirmes the incremental benefit of PET staging over conventional radiological imaging in the management of MCC patients with unsuspected diffuse pancreas involvement. Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. Aim: It is well known that breast feeding is totally contra-indicated following I131 treatment for thyrotoxicosis, since I131 is freely expressed in breast milk. However lactation can continue for some time after breastfeeding stops and this can lead to significantly increased breast dose. Methods: ICRP95 developed a comprehensive model for the lactating breast, and breast dose during lactation was calculated. For I131, only one dose model was presented. This was based on normal 30 % uptake by the mother, 270 ml/24 hr milk production, with a further 40 ml milk production stimulated by breast feeding. Results: The breast dose without lactation for 600 MBq I131 (30% uptake) is 36 mSv. The ICRP95 figure with their lactation model is 780 mSv, a 21x increase. Surprisingly, ICRP95 comment that the increased breast dose is small in relation to overall effective dose. Lactation I131 levels follow plasma levels. So for thyrotoxicosis with an increased thyroid uptake of 55 % the calculated breast dose is 1.2Sv. For ablation with 1.1GBq, the rapid excretion of I131 leads to some breast dose reduction. But calculation suggests a breast dose of 830 mSv, still a high figure. Conclusion: For I131 treatment, the lactation status needs to be considered to reduce breast dose. However suddenly stopping breastfeeding is not recommended and Maternity advice should be sought. Most women can reduce lactation to negligible levels in about 2 weeks with help. In difficult cases, Cabergolin may be considered as an effective mechanism, but can have side effects. Maternity advice is that this is rarely needed. Although uncommon, this situation should be added to local guidance. Results: 83 patients showed no relevant uptake. In 21 we suspected a malignoma, which was proven in 9 cases by surgery and histology. The rest (105 patients) showed conspicuous focal uptake (SUV > 2.5), which was interpreted by us or after exclusion of malignant disease as inflammatory (tuberculosis, sarcoidosis and non-granulomatous). In 35 cases (18 m, 17 f, 45.4 ± 18 y) we do not only have proof of tuberculotic disease other than by FDG-PET, but also ≥ 1 follow-up PET/CTs. We stratified our results according to involved systems: lung and pleura / LN intrathor. / LN extrathor. / bones / visceral organs / other soft tissue. 1 patient remained without FDG-uptake, 15 showed 1 involved system, 13 had lesions in 2, 1 in 3 and 5 in 4. The figures extracted from Xray-CT alone are 12/0 (incl. one false negative also with FDG), 13/1, 9/2, 1/3, none with 4 or more involved systems. Aim: The paper is to discuss some current specific difficulties in assessing the radiation exposure received by workers handling radiopharmaceuticals at nuclear medicine clinics or departments engaged in the PET/CT examinations. This staff is daily coming into contact with unsealed radioactive material which results in its whole-body exposure as well as in the exposure of extremities, especially the skin of hands. Methods: The present situation in radiation exposures of extremities of radiation workers has been summarized and the specific problems in monitoring the skin dose identified. The equivalent dose to the skin of hands of workers at selected nuclear medicine departments in the Czech Republic have been measured and compared against relevant dose limits. Results: The distribution of the dose on the surface of fingers at specified positions monitored by TLDs is presented. The relation between the readings of finger dosimeters and the maximum skin exposure was analysed and interpreted. The preliminary results have shown that about 5 % of workers handling F-18 labelled radiopharmaceuticals may exceed the current dose limit for the skin.
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